The Annual General Meeting was held in accordance with the published agenda
(announcement dated March 22, 2012). 

The General Meeting took note of the report on the Company’s activities and
adopted the Annual Report 2011. Also, the General Meeting adopted the proposed
decision on use of profit/loss. 

The board fee for 2012 was approved.

All board members were up for election. Carsten Lønfeldt, Peter Nordkild, Niels
T. Foged and Marianne Weile were re-elected. After the meeting the Board
constituted itself with Carsten Lønfeldt as chairman. 

Deloitte was re-elected auditor for BioPorto A/S.

All proposals from the Board of Directors in the agenda’s item 6 were carried:

  1. The board is authorized for a period of 18 months after the Annual General
     Meeting to let the company buy back its own shares up to 10% of the then
     remaining shares
  2. The authorization 
in article § 16 to increase the share capital is adjusted according to the
     Danish Business Authority's new practice, so that the authority is divided
     into two authorizations to increase share capital with and without
     pre-emption rights for existing shareholders. In addition, the
     authorizations are extended to 17 April 2017, with a maximum increase of
     DKK 80 million corresponding to the balance under the current
     authorization.
  3. The authorization 
in article § 17 to issue convertible debt instruments capital is adjusted
     according to the Danish Business Authority's new practice, so that the
     authority is divided into two authorizations to issue convertible debt
     instruments with and without preemptive rights for existing shareholders.
     In addition, the authorizations are extended to March 31 2017, with a
     maximum increase of DKK 36.050.000 corresponding to the balance under the
     current authorization.
  4. Changes to the Company Articles
     1. Article 6, paragraph 3: The provision is deleted, so that shareholders
        and others who have requested to receive material relating to the
        general meeting, no longer need to renew the application every 3 years.
     2. Article 7, paragraph 2: 
The provision is adapted so that it follows the wording of the Companies
        Act § 84
     3. Article 8, paragraph 3: The wording is modernized and that the
        consideration of proposals from the board and shareholders, including a
        proposal authorizing the Company to acquire own shares, will be on the
        agenda for each AGM
     4. Article 12, paragraph 4: It is apparent  that the General Meeting
        determines the remuneration of all board members, including any employee
        representatives

Gentofte, April 17, 2012



BioPorto A/S

The Board of Directors


         Further information:
         Frank Harder, CFO
         Thea Olesen, CEO
         Tel. no. (+45) 45 29 00 00, e-mail investor@bioporto.com